newsfilter
← Latest News
Business Wire·

Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

TAZVERIK® (tazemetostat) Net Product Revenue of $11.6 Million for 4Q 2021; $30.9 Million for FY 2021 $85 Million in Gross Proceeds Raised in January 2022 Public Offering, Combined with Recent Expense Reductions Announced Today, Extends Cash Runw